TY - JOUR
T1 - The Boosting Potential of Bacteria in Cancer Immunotherapy
AU - Binder, David C.
AU - Wainwright, Derek A.
N1 - Funding Information:
This work was supported NIH grants K99 NS082381 (D.A.W.), R00 NS082381 (D.A.W.), and R01 NS097851-01 (D.A.W.); Robert H. Lurie Comprehensive Cancer Center [Zell Scholar Program of the Zell Family Foundation Gift (D.A.W.)]; and Cancer Research Institute (Clinic and Laboratory Integration Program).
Publisher Copyright:
© 2017 Elsevier Ltd
PY - 2017/7
Y1 - 2017/7
N2 - Salmonella Typhimurium, engineered to express flagellin B, recently demonstrated unprecedented tumor control through a TLR-dependent mechanism. Here, we review new observations that support the potential of utilizing modified bacteria to enhance antitumor immunity. We also discuss the implications of these findings for clinical applications, including immune checkpoint blockade therapies.
AB - Salmonella Typhimurium, engineered to express flagellin B, recently demonstrated unprecedented tumor control through a TLR-dependent mechanism. Here, we review new observations that support the potential of utilizing modified bacteria to enhance antitumor immunity. We also discuss the implications of these findings for clinical applications, including immune checkpoint blockade therapies.
UR - http://www.scopus.com/inward/record.url?scp=85020110480&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85020110480&partnerID=8YFLogxK
U2 - 10.1016/j.molmed.2017.05.008
DO - 10.1016/j.molmed.2017.05.008
M3 - Short survey
C2 - 28583420
AN - SCOPUS:85020110480
VL - 23
SP - 580
EP - 582
JO - Trends in Molecular Medicine
JF - Trends in Molecular Medicine
SN - 1471-4914
IS - 7
ER -
